Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management

doi:10.3748/wjg.v30.i35.3942

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 35

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-1)

Sum=0

Sep 21, 2024 (publication date) through Sep 13, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Sep 21, 2024; 30(35): 3942-3953
Published online Sep 21, 2024. doi: 10.3748/wjg.v30.i35.3942

Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management

Antonio M Caballero-Mateos, Guillermo Arturo Cañadas-de la Fuente

Antonio M Caballero-Mateos, Department of Gastroenterology and Hepatology, San Cecilio University Hospital, Granada 18014, Spain

Guillermo Arturo Cañadas-de la Fuente, Department of Nursing, Faculty of Health Sciences, University of Granada, Granada 18004, Spain

Author contributions: Caballero-Mateos AM contributed to the conception, design, and drafting of the manuscript; Cañadas-de la Fuente GA contributed to the design and revision of the manuscript.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Antonio M Caballero-Mateos, PhD, Assistant Lecturer, Doctor, Gastroenterology and Hepatology Department, San Cecilio University Hospital, AV conocimiento sn, Granada 18014, Spain. ogy1492@hotmail.com

Received: July 6, 2024
Revised: August 19, 2024
Accepted: August 22, 2024
Published online: September 21, 2024
Processing time: 68 Days and 1.6 Hours

Core Tip

Core Tip: Janus kinase inhibitors such as tofacitinib, filgotinib, and upadacitinib represent a significant advancement in ulcerative colitis (UC) management, offering effective induction and maintenance of remission, especially for patients unresponsive to conventional therapies. Despite potential safety concerns, these agents provide rapid action and the ability to tailor treatment to individual patient needs, marking a paradigm shift in UC treatment strategies.